This company has been acquired
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Alimera Sciences Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
Alimera Sciences has a total shareholder equity of $38.8M and total debt of $69.7M, which brings its debt-to-equity ratio to 179.8%. Its total assets and total liabilities are $150.4M and $111.6M respectively. Alimera Sciences's EBIT is $2.4M making its interest coverage ratio 0.2. It has cash and short-term investments of $10.8M.
Anahtar bilgiler
179.8%
Borç/özkaynak oranı
US$69.73m
Borç
| Faiz karşılama oranı | 0.2x |
| Nakit | US$10.83m |
| Eşitlik | US$38.79m |
| Toplam yükümlülükler | US$111.59m |
| Toplam varlıklar | US$150.38m |
Son finansal sağlık güncellemeleri
Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Recent updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story
Feb 15Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)
Oct 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data
Oct 06Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland
Sep 20Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection
Aug 09Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection
Jul 22Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation
Jul 08Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?
Nov 06Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Aug 24Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares
Feb 11Alimera Sciences (ALIM) Investor Presentation - Slideshow
Nov 18Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: ALIM's short term assets ($55.4M) exceed its short term liabilities ($19.8M).
Uzun Vadeli Yükümlülükler: ALIM's short term assets ($55.4M) do not cover its long term liabilities ($91.8M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: ALIM's net debt to equity ratio (151.9%) is considered high.
Borcun Azaltılması: ALIM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: ALIM has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if ALIM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.